Business
Anixa Biosciences Announces Completion of Cchek(TM) Analytical Verification at CLIA Laboratory
SAN JOSE, Calif., May 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"\n \n \n \n \n SAN JOSE, Calif., May 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test successfully passed all required initial analytical verification studies en route to commercialization and implementation in the ResearchDx facility. \n\n \nHaving completed this major validation milestone, ResearchDx, a CLIA-certified laboratory, is now processing the clinical trial samples received from Anixa's study collaborators and incorporating the resulting data into the Anixa Artificial Intelligence Training Dataset. This signals the start of the Database Generation phase of the ResearchDx clinical validation of Anixa's Cchek™ PCC test.\nDr. Amit Kumar, CEO of Anixa Biosciences, stated, \"We are pleased to announce the successful completion of the Initial Assay Verification. We are now actively building and training the required Neural Network. This milestone demonstrates that we have advanced Cchek™ from a research environment to a commercial laboratory, an important milestone on our path to commercialization.\"\nDr. Mathew Moore, Principal of ResearchDx, stated, \"The Cchek™ PCC test is a novel and highly sensitive assay designed for the early detection of prostate cancer. We are excited to continue to collaborate with Anixa on its innovative Cchek™ platform, and we look forward to the process of commercialization of the Cchek™ technology.\"\nAbout Anixa Biosciences, Inc.Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa is developing a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T. Its Cchek™ liquid biopsy technology is a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is most curable. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.\nAbout ResearchDxResearchDx is a \"full...